Accredited Educational Activities

A Close Look at the Diagnosis and Treatment of Patients with Retinal Vascular Disease

This online activity targets healthcare gaps related to the diagnosis and management of diabetic retinopathy (DR), age-related macular degeneration (AMD), and retinal vein occlusion (RVO), impacting outcomes through risk stratification, diagnostic strategies, and treatment individualization with anti-VEGF agents.


Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Retinal Vein Occlusion – VA Grand Rounds Enduring Activity
Apr 22 2021 @ 5:19 am – Jul 29 2022 @ 6:19 am

Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Retinal Vein Occlusion – VA Grand Rounds Enduring Activity



David Eichenbaum, MD, FAAO

Collaborative Associate Professor
Department of Ophthalmology
University of South Florida Morsani College of Medicine
Director of Research
Retina Vitreous Associates of Florida
St. Petersburg, FL


This online activity targets healthcare gaps correlated with screening, multidisciplinary care and timely intervention in retinal vein occlusion (RVO), which can impact vision-related quality of life.

  • By addressing these gaps, you can assess whether your approach to RVO management through screening, utilization of clinical trial data to guide appropriate treatment and multidisciplinary coordination for comprehensive RVO management – could be modified to help both strategize treatment design and close these gaps.
  • Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing impact that RVO can have on vision-related quality of life.
  • You will also be immersed in dynamic whiteboard animations to memorably highlight key points related to how the inflammatory and vascular endothelial growth factor (VEGF) pathways lead to the development of RVO, as well as the fundoscopic retinal changes associated with the various types of RVO and their subsequent consequences.


This online activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, primary care providers, managed care providers, pharmacists and other healthcare providers who manage patients with retinal vein occlusion.


  • Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for RVO
  • Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for RVO
  • Identify pathogenic changes in RVO that would be best managed with a multidisciplinary approach
  • Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of RVO


Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


Purpose: This program would be beneficial for nurses involved in the care of patients with retinal vein occlusion.

CNE Credits: 1.0 ANCC Contact Hour.


Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.


Faculty Member Disclosures
David Eichenbaum, MD, FAAO Has worked as a consultant for Alimera, Allergan, Apellis, EyePoint, DORC, Genentech, Gyroscope, IvericBio, KKR, Kodiak, Notal Vision, Novartis, RecensMedical, Regeneron.  He has worked as a speaker for Allergan, Bayer, DORC, EyePoint, Genentech, Novartis, and an Investigator for Alkahest, AsclepiX, AvericBio, Bayer, Chengu, Genentech, Gemini, Gyroscope, Ionis, IvericBio, Kodiak, Mylan, NGM, Novartis, Ocular Therapeutix, Opthea, RecensMedical, Regeneron.  He owns equity / stock in Clearside, US Retina, Hemera Biopharmaceuticals, Boston Image Reading Center, Network Eye, and he is the Founder of Network Eye.

CME Content Review

The content of this activity was independently peer-reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer-reviewed by a nurse reviewer.

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Marissa Mays-Verman, Program Manager of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.


Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.


There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete online pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at


Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM)
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.



Scroll to Top


Clinician Scientific & Educational Resources

The RELIEF Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for Retinal Vein Occlusion (RVO) in patients with diabetes who have or are at risk for developing RVO. Click on one of the options below to learn more about RVO.

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2019 | Retinal Vein Occlusion | All Rights Reserved | Website by Divigner

Scientific Council

Neil M. Bressler, MD

James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Baltimore, MD

A. Paul Chous, MA, OD, FAAO

Specializing in Diabetes Eye Care & Education, Chous Eye Care Associates
Adjunct Professor of Optometry, Western University of Health Sciences
AOA Representative, National Diabetes Education Program
Tacoma, WA

Steven Ferrucci, OD, FAAO

Chief of Optometry, Sepulveda VA Medical Center
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Sepulveda, CA

Julia A. Haller, MD

Wills Eye Hospital
Philadelphia, PA

Allen C. Ho, MD, FACS

Director, Retina Research
Wills Eye Hospital
Professor and Chair of the Department of Ophthalmology
Thomas Jefferson University Hospitals
Philadelphia, PA

Charles C. Wykoff, MD, PhD

Director of Research, Retina Consultants of Houston
Associate Professor of Clinical Ophthalmology
Blanton Eye Institute & Houston Methodist Hospital
Houston, TX